Nyxoah SA (Nyxoah (NYXH)) is catching a small bid in Tuesday's premarket session, with shares up about 4.3% to $1.45. That's a welcome reprieve for a stock that's lost nearly 70% of its value so far this year. The catalyst? A freshly priced $95 million public offering that gives the company some serious financial firepower.

On Friday, Nyxoah priced its underwritten public offering of roughly 55.2 million ordinary shares at $1.72 each. Underwriters also get a 30-day option to buy additional shares. The proceeds are earmarked for two big priorities: expanding commercialization activities in the U.S. and advancing R&D for the Genio system, a treatment for Obstructive Sleep Apnea.

This is a significant capital raise for a company with a market cap that's been shrinking. It shows Nyxoah is serious about building its U.S. presence and improving its product lineup, even as the stock has taken a beating.

Leadership Shake-Up to Accelerate U.S. Growth

Just last Thursday, Nyxoah announced a leadership transition that signals a new chapter. After seven years as CEO, Olivier Taelman decided to step down. The Board has formally launched a search for a new U.S.-based CEO, a move aimed at accelerating commercial traction in the American market.

The timing makes sense. Nyxoah's Q1 results, reported recently, showed a loss of $0.43 per share—better than the consensus loss of $0.54. Revenue came in at $7.46 million, beating the $7.13 million consensus. And the company's fiscal 2026 sales guidance of $42.16 million to $46.84 million is well above the $37.2 million analysts were expecting. So the business is growing, but the stock has been hammered.

Technical Picture: Oversold but Still Bearish

Let's talk about the chart, because it's a doozy. Nyxoah shares are currently trading at $1.42, which is about 48.3% below their 20-day simple moving average of $2.79. The relative strength index (RSI) is at 19.67—deep in oversold territory. That can sometimes signal a potential reversal if buyers step in.

But the trend is still bearish. The 20-day SMA is below the 50-day SMA, which is a classic sign that momentum is lacking. So while the stock might be due for a bounce, the overall direction remains down until proven otherwise.

What Analysts Think

Despite the stock's slide, Wall Street still sees value. Nyxoah carries a consensus Buy rating with an average price target of $7.67—that's more than five times the current price. Recent analyst moves include:

• Piper Sandler: Overweight, but lowered its forecast to $7.00 on May 13.
• Stifel: Downgraded to Hold, with a $5.00 forecast on May 12.

So while the bulls are still in charge, the downgrade from Stifel shows some caution creeping in.

For now, Nyxoah has the cash to execute its U.S. expansion and keep developing the Genio system. Whether that will be enough to turn the stock around is the million-dollar—or in this case, $95 million—question.